Market research
HJLI Hancock Jaffe Laboratories Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 98M
- P/E ratio
- Not available
- Analyst target
- 26
- Dividend yield
- 0.0%
- Beta
- 1.54
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Medical Devices
- ISIN
- US29415J1060
- Market cap
- 98M
- P/E ratio
- Not available
- Analyst target
- 26
- Dividend yield
- 0.0%
- Beta
- 1.54
About
About Hancock Jaffe Laboratories Inc
Hancock Jaffe Laboratories, Inc., a medical device company, develops and sells tissue-based solutions for patients with cardiovascular disease, and peripheral arterial and venous disease in the United States and Europe. It engages in the development and manufacture of bioprosthetic medical devices for cardiovascular diseases, including the VenoValve, a porcine based device to be surgically implanted in the deep venous system of the leg to treat reflux associated with chronic venous insufficiency; and the CoreoGraft, a bovine based off the shelf conduit to be used to revascularize the heart during coronary artery bypass graft surgeries. The company was founded in 1987 and is headquartered in Irvine, California. Hancock Jaffe Laboratories, Inc. is a subsidiary of Leman Cardiovascular SA.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the HJLI discussion.
5 years, 4 months ago
Hancock Jaffe Laboratories, Inc is currently in a long term downtrend where the price is trading 6.1% below its 200 day moving average.
From a valuation standpoint, the stock is 83.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 216.9.
Hancock Jaffe Laboratories, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 90.9% to $-4M since the same quarter in the previous year.
Finally, its free cash flow fell by 61.4% to $-3M since the same quarter in the previous year.
Based on the above factors, Hancock Jaffe Laboratories, Inc gets an overall score of 1/5.